TRISALUS LIFE SCIENCES INC (TLSI) Fundamental Analysis & Valuation

NASDAQ:TLSIUS89680M1018

Current stock price

4.185 USD
+0.18 (+4.62%)
Last:

This TLSI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TLSI Profitability Analysis

1.1 Basic Checks

  • In the past year TLSI has reported negative net income.
  • In the past year TLSI has reported a negative cash flow from operations.
  • In multiple years TLSI reported negative net income over the last 5 years.
  • TLSI had a negative operating cash flow in each of the past 5 years.
TLSI Yearly Net Income VS EBIT VS OCF VS FCFTLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • TLSI has a Return On Assets of -201.28%. This is amonst the worse of the industry: TLSI underperforms 88.01% of its industry peers.
Industry RankSector Rank
ROA -201.28%
ROE N/A
ROIC N/A
ROA(3y)-198.15%
ROA(5y)-113.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSI Yearly ROA, ROE, ROICTLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • TLSI has a Gross Margin of 84.57%. This is amongst the best in the industry. TLSI outperforms 87.43% of its industry peers.
  • The Profit Margin and Operating Margin are not available for TLSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSI Yearly Profit, Operating, Gross MarginsTLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

2

2. TLSI Health Analysis

2.1 Basic Checks

  • TLSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TLSI has more shares outstanding than it did 1 year ago.
  • TLSI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TLSI is higher compared to a year ago.
TLSI Yearly Shares OutstandingTLSI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
TLSI Yearly Total Debt VS Total AssetsTLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -11.51, we must say that TLSI is in the distress zone and has some risk of bankruptcy.
  • TLSI has a worse Altman-Z score (-11.51) than 75.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.51
ROIC/WACCN/A
WACC9.81%
TLSI Yearly LT Debt VS Equity VS FCFTLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.80 indicates that TLSI has no problem at all paying its short term obligations.
  • TLSI has a Current ratio of 2.80. This is in the lower half of the industry: TLSI underperforms 65.76% of its industry peers.
  • TLSI has a Quick Ratio of 2.54. This indicates that TLSI is financially healthy and has no problem in meeting its short term obligations.
  • TLSI's Quick ratio of 2.54 is on the low side compared to the rest of the industry. TLSI is outperformed by 67.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.54
TLSI Yearly Current Assets VS Current LiabilitesTLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 10M 20M 30M

5

3. TLSI Growth Analysis

3.1 Past

  • TLSI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.79%, which is quite good.
  • Looking at the last year, TLSI shows a very strong growth in Revenue. The Revenue has grown by 25.81%.
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.5%
Revenue 1Y (TTM)25.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.85%

3.2 Future

  • Based on estimates for the next years, TLSI will show a very strong growth in Earnings Per Share. The EPS will grow by 48.03% on average per year.
  • Based on estimates for the next years, TLSI will show a very strong growth in Revenue. The Revenue will grow by 35.38% on average per year.
EPS Next Y77.96%
EPS Next 2Y48.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.4%
Revenue Next 2Y37.34%
Revenue Next 3Y35.89%
Revenue Next 5Y35.38%

3.3 Evolution

TLSI Yearly Revenue VS EstimatesTLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
TLSI Yearly EPS VS EstimatesTLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

1

4. TLSI Valuation Analysis

4.1 Price/Earnings Ratio

  • TLSI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TLSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSI Price Earnings VS Forward Price EarningsTLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSI Per share dataTLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TLSI's earnings are expected to grow with 48.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.03%
EPS Next 3YN/A

0

5. TLSI Dividend Analysis

5.1 Amount

  • No dividends for TLSI!.
Industry RankSector Rank
Dividend Yield 0%

TLSI Fundamentals: All Metrics, Ratios and Statistics

TRISALUS LIFE SCIENCES INC

NASDAQ:TLSI (4/1/2026, 3:17:48 PM)

4.185

+0.18 (+4.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)05-18
Inst Owners19.34%
Inst Owner Change11.46%
Ins Owners15.17%
Ins Owner Change9.28%
Market Cap256.58M
Revenue(TTM)45.15M
Net Income(TTM)-71.12M
Analysts83.08
Price Target9.38 (124.13%)
Short Float %2.77%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-60.67%
Min EPS beat(2)-64.97%
Max EPS beat(2)-56.36%
EPS beat(4)0
Avg EPS beat(4)-54.06%
Min EPS beat(4)-73.8%
Max EPS beat(4)-21.11%
EPS beat(8)3
Avg EPS beat(8)-13.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.75%
Min Revenue beat(2)-3.58%
Max Revenue beat(2)2.08%
Revenue beat(4)2
Avg Revenue beat(4)0.2%
Min Revenue beat(4)-3.58%
Max Revenue beat(4)2.81%
Revenue beat(8)4
Avg Revenue beat(8)0.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20%
PT rev (3m)-18.99%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-90.24%
EPS NY rev (1m)3.97%
EPS NY rev (3m)-11.69%
Revenue NQ rev (1m)-25.13%
Revenue NQ rev (3m)-26.97%
Revenue NY rev (1m)-3.85%
Revenue NY rev (3m)-7.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.68
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.74
BVpS-0.55
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -201.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.57%
FCFM N/A
ROA(3y)-198.15%
ROA(5y)-113.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 146.65%
Cap/Sales 2.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.54
Altman-Z -11.51
F-Score2
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)92.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.13%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.5%
EPS Next Y77.96%
EPS Next 2Y48.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)25.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%59.85%
Revenue Next Year35.4%
Revenue Next 2Y37.34%
Revenue Next 3Y35.89%
Revenue Next 5Y35.38%
EBIT growth 1Y25.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.35%
EBIT Next 3Y35.69%
EBIT Next 5Y29.19%
FCF growth 1Y54.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.9%
OCF growth 3YN/A
OCF growth 5YN/A

TRISALUS LIFE SCIENCES INC / TLSI Fundamental Analysis FAQ

What is the fundamental rating for TLSI stock?

ChartMill assigns a fundamental rating of 2 / 10 to TLSI.


What is the valuation status of TRISALUS LIFE SCIENCES INC (TLSI) stock?

ChartMill assigns a valuation rating of 1 / 10 to TRISALUS LIFE SCIENCES INC (TLSI). This can be considered as Overvalued.


How profitable is TRISALUS LIFE SCIENCES INC (TLSI) stock?

TRISALUS LIFE SCIENCES INC (TLSI) has a profitability rating of 1 / 10.